Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 07/29 10:00:16 pm
125.23 USD   +0.62%
07/28 Weak China sales drag down Smith & Nephew profits
07/27DJExperimental Alzheimer's Drug Fails in Trial
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J d..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

J&J's Simponi Helps Colitis Patients In Clinical Trial

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/21/2012 | 08:45pm CEST
   By Peter Loftus 
   Of  
 

Johnson & Johnson (>> Johnson & Johnson) said its drug Simponi improved symptoms in a majority of patients with an inflammatory-bowel disease in a new clinical trial.

The results, released at a medical conference Monday, could support expansion of the approved uses of Simponi to include treating the bowel condition, known as ulcerative colitis, which J&J estimates affects about 700,000 people in the U.S.

Simponi, which was introduced in 2009, is currently approved to treat signs and symptoms of moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis.

Simponi is known as an anti-tumor necrosis factor, or anti-TNF, a category that also includes J&J's older drug, Remicade, which is already approved to treat ulcerative colitis. Simponi can be self-administered by patients as an injection, while Remicade requires intravenous infusion by a health-care provider.

J&J recorded $410 million in Simponi sales for 2011; Merck & Co. (MRK), which markets the drug in certain countries outside the U.S., recorded $264 million in Simponi sales for 2011.

J&J tested Simponi in a late-stage clinical trial of more than 770 patients with moderately to severely active ulcerative colitis who had failed to respond to or tolerate certain other treatments.

Some patients received Simponi--at two different dose levels--and some received a placebo, and researchers tracked how many experienced a clinical response at six weeks after the start of treatment. Clinical response included improvements in various symptoms of ulcerative colitis such as diarrhea.

According to J&J, 51.8% and 55% of patients in the two Simponi groups, respectively, achieved a clinical response at week 6, versus 29.7% of placebo patients. The results were presented Monday at the Digestive Disease Week medical meeting in San Diego.

In a secondary measure in the trial, roughly 18.7% and 17.8% of patients in the Simponi groups had clinical remission, versus 6.3% in placebo patients.

The rates of adverse events were comparable among the Simponi and placebo groups, and J&J said the safety of Simponi in the colitis study was consistent with the drug's safety profile in the diseases for which it's already approved.

As a class of drugs, Simponi and other anti-TNFs are associated with increased risk of infections and certain forms of cancer such as lymphoma.

The data suggest Simponi could be a new treatment option for ulcerative colitis patients who don't respond to other drugs, or who prefer the convenience of a subcutaneous injection, said William Sandborn, chief of the division of gastroenterology at the University of California, San Diego, and lead investigator of the J&J-funded study.

J&J also has studied Simponi over a longer treatment duration in colitis patients, and results are expected later this year.

J&J plans to apply for U.S. and European regulatory approval of Simponi as a treatment for ulcerative colitis this year, said J&J spokesman Brian Kenney.

Abbott Laboratories (>> Abbott Laboratories) also has applied for regulatory approval of its anti-inflammatory drug, Humira, as a treatment for ulcerative colitis. European regulators have approved the new indication.

Last year, the FDA declined to approve J&J's requests to market Simponi's ability to inhibit progression of structural damage in both rheumatoid arthritis and psoriatic arthritis.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Johnson & Johnson, Abbott Laboratories
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
07/29 JOHNSON & JOHNSON : Operation Family Caregiver Expands to Washington State and N..
07/28 Johnson & Johnson Reports 2016 Second-Quarter Results
07/28 JOHNSON & JOHNSON : RefleXion Medical Extends Series B Financing to $52 Million ..
07/28 Weak China sales drag down Smith & Nephew profits
07/27DJExperimental Alzheimer's Drug Fails in Trial
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J deal
07/26 JOHNSON & JOHNSON : Janssen Announces Clinical Collaboration with Bristol-Myers ..
07/26 JOHNSON & JOHNSON : Daratumumab (DARZALEX®) Granted Breakthrough Therapy Designa..
07/26 JOHNSON & JOHNSON : J&J reports progress on anti-HIV vaccine
07/25 JOHNSON & JOHNSON : J&J's Acclarent To Pay U.S. $18 Mln To Settle False Claims A..
More news
Sector news : Pharmaceuticals - NEC
01:14a BAYER : says will halt future U.S. sales of insecticide
07/29DJTech Stocks Up On Google Earnings - Tech Roundup
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/28 Guest Charles Gooch, Jr. (Part 2) - Dividend Health Checkup Podcast - Episode..
07/27 Johnson & Johnson Delivers Strong Results
07/27 How To Retire At 62 And Live To 120 On Only A Million Bucks
07/27 Concentrating Investing Can Boost Portfolio Returns - Part II
07/27 Pivotal Discontinuation Ends Tokai Misery Early
Advertisement
Financials ($)
Sales 2016 72 070 M
EBIT 2016 21 664 M
Net income 2016 16 515 M
Finance 2016 14 587 M
Yield 2016 2,52%
P/E ratio 2016 21,15
P/E ratio 2017 18,71
EV / Sales 2016 4,55x
EV / Sales 2017 4,27x
Capitalization 342 345 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 1,5%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.16%342 345
PFIZER INC.13.60%222 398
ROCHE HOLDING LTD.-9.99%215 597
NOVARTIS AG-5.30%214 061
MERCK & CO., INC.10.62%161 736
BRISTOL-MYERS SQUIBB C..8.53%124 630
More Results